Technical 'support stack' is actually a breakdown warning with the 50 SMA just 23 cents away from triggering a medium-term breakdown

• Close at $61.61 was at the low of the session after opening at $62.43 — intraday sell-off of nearly $1 on 7.7M-volume day
• Four consecutive lower highs from the August 24 peak of $64.70
• 10 EMA has rolled over from $63.57 to $62.75, price is $1.14 below it
• MACD crossed below signal line around August 25-26, histogram at -0.27 and widening
• RSI slid from 66 in late July to 45 today
• Downside to lower Bollinger Band at $60.94: -$0.67; Upside to 10 EMA at $62.75: +$1.14
• If 50 SMA breaks (0.4% move), no next major support until $58.30 — a 5.4% drop

↩ rebuts: “Bull's 'asymmetric risk-reward' framing and 'ATR is compressed at 1.32' argument that compressed ATR precedes expansion to downside”

Cocoa normalization is not the same as margin recovery — MDLZ uses forward contracts and hedges 6-12 months out, meaning cost relief won't hit COGS until late 2026 or 2027

• MDLZ locked in high-priced cocoa contracts through bulk of 2025-early 2026
• Cocoa price decline in futures market doesn't hit MDLZ's COGS until late 2026-2027
• The 'cocoa recovery' has already happened in input-cost futures; hasn't been confirmed flowing through MDLZ's relevant forward periods

↩ rebuts: “Bull's '2025 margin collapse is cyclical' narrative and '23% forward EPS recovery already priced in' assumption”

Forward EPS estimates are guesses that get revised, not facts — 2025 started with constructive estimates and ended at $1.89 actual, well below consensus

• Going into 2025, sell-side had constructive estimates — actual print came in at $1.89
• Sell-side has chronic tendency to be late to deteriorating fundamentals and optimistic on recovery
• Realistic risk: $3.36 estimate gets cut to $2.80; forward P/E stays around 22x, PEG<1 narrative evaporates

↩ rebuts: “Bull's PEG <1 argument based on $3.36 EPS consensus estimate”

Revenue grew 5.7% but inventory rose 15.5% YoY to $4.42B — inventory growing more than 2x the rate of revenue signals demand weakness, not stockpiling

• Revenue grew from $36.44B in 2024 to $38.54B in 2025 — a 5.7% increase
• Inventory rose 15.5% YoY to $4.42B
• When inventory grows more than 2x revenue rate, demand is likely weakening and product is piling up

↩ rebuts: “Bull's 'operating leverage on both sides' thesis requiring sticky pricing AND falling input costs AND volume recovery”

Underperformance versus S&P is a structural de-rating signal, not a 'left behind' setup — capital rotating away means marginal investor doesn't believe the 23% earnings recovery

• MDLZ up 2.8% over six months while S&P up 12.1%
• S&P names driving returns are mega-cap tech, AI infrastructure, semiconductors — MDLZ competes for capital with growth names and yield anchors
• Post-earnings drift has been ongoing for six months, not 30 days
• 6.1% yield is compensation for risk, not a floor — Treasury yields at ~4%+ with zero principal risk beat MDLZ's risk-adjusted return

↩ rebuts: “Bull's 'left behind in risk-on tape' framing and 'where else are you getting paid 6%' argument”

Low beta of 0.40 means MDLZ doesn't participate in market rallies — in current risk-on regime, MDLZ underperforms by 6-11%

• Scenario A: Risk-on continues, S&P up 10-15%, MDLZ returns 2-4% — underperform by 6-11%
• Scenario B: Risk-off hits, forward earnings are a bet that gets punished
• Scenario C (most likely): Stagflation/com modity-led reflation squeezes MDLZ from both sides — input costs elevated while consumer wallets squeezed

↩ rebuts: “Bull's 'defensive ballast' argument — in 2022-2023 defensives got crushed alongside everything else due to rate component”

Capital return story is funded by debt and depends on FCF recovery that barely covers dividend — Net Debt/EBITDA surged from 2.0x to 3.8x in one year

• Net debt rose $2.7B in 2025 to $3.8x Net Debt/EBITDA
• Dividend ($2.49B) plus buybacks ($2.39B) totaled $4.88B against FCF of only $3.24B
• MDLZ returned $1.64B more than it generated in cash, funded by debt
• Goodwill and intangibles are 61.5% of total assets ($43.96B)
• If 2026 FCF comes in at $3.0B instead of $3.5B, dividend coverage gets thin
• Dividend cut would re-rate stock to high-yield-pension-fund-discount territory: 14-16x earnings, not 18-22x

↩ rebuts: “Bull's 'investment grade with comfortable cushion' framing”

Grenade protein bar U.S. launch is not material — limited brand recognition, dominated by Quest/RXBAR/ONE, MDLZ didn't disclose revenue contribution guidance because it isn't material

• Grenade is a UK brand with limited U.S. brand recognition
• U.S. protein bar market dominated by Quest, RXBAR, ONE
• MDLZ using existing distribution means cannibalization risk and limited greenfield
• Category is high-competition, low-margin-at-scale, dominated by digitally native brands
• MDLZ didn't disclose revenue contribution guidance for Grenade U.S.

↩ rebuts: “Bull's catalyst A (Grenade protein bar U.S. launch)”

Oreo limited-edition flavors are a declining volume indicator, not a growth catalyst — defensive marketing to maintain cultural relevance, not expand market share

• Limited-edition flavors signal core SKUs are maturing
• Food Dive framing: 'keeping it on top' means defending market share, not expanding it

↩ rebuts: “Bull's 'consumer-acquisition headlines' framing for Oreo innovation”

Broad commodity strength YTD creates input cost headwind beyond just cocoa — sugar, dairy, wheat, packaging materials, energy all commodity-linked

• Commodity strength YTD is broad-based, not just cocoa
• Oil is up. Broad commodity baskets are leading
• DOJ antitrust scrutiny expanding into retail/beef pricing signals FMCG pricing-power scrutiny
• Fed on hold at 89% probability — no multiple expansion catalyst
• Risk-on tape actively bad for MDLZ — capital goes to cyclicals and growth, not defensives

↩ rebuts: “Bull's disinflation/easing yields macro thesis”